Citigroup
JNCE

Citigroup’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Citigroup’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-425
Closed -$472 – 6003
2022
Q4 		$472 Sell
425
-977
-70% -$1.39K ﹤0.01% 5515
2022
Q3 		$3K Sell
1,402
-54,791
-98% -$194K ﹤0.01% 5446
2022
Q2 		$170K Buy
56,193
+53,671
+2,128% +$261K ﹤0.01% 3941
2022
Q1 		$17K Sell
2,522
-7,350
-74% -$52.4K ﹤0.01% 5262
2021
Q4 		$82K Buy
9,872
+3,503
+55% +$28.9K ﹤0.01% 4828
2021
Q3 		$47K Buy
6,369
+1,696
+36% +$10.5K ﹤0.01% 4770
2021
Q2 		$32K Buy
4,673
+2,663
+132% +$22.1K ﹤0.01% 5054
2021
Q1 		$21K Sell
2,010
-2,424
-55% -$26.5K ﹤0.01% 5241
2020
Q4 		$31K Buy
4,434
+3,605
+435% +$28.1K ﹤0.01% 6382
2020
Q3 		$7K Sell
829
-2,184
-72% -$13.5K ﹤0.01% 6864
2020
Q2 		$21K Sell
3,013
-2,834
-48% -$15.3K ﹤0.01% 6583
2020
Q1 		$28K Buy
5,847
+825
+16% +$4.75K ﹤0.01% 6467
2019
Q4 		$44K Buy
5,022
+286
+6% +$1.55K ﹤0.01% 6419
2019
Q3 		$16K Buy
4,736
+604
+15% +$2.42K ﹤0.01% 6870
2019
Q2 		$21K Sell
4,132
-134
-3% -$712 ﹤0.01% 7069
2019
Q1 		$26K Sell
4,266
-1,794
-30% -$8.67K ﹤0.01% 6819
2018
Q4 		$20K Buy
6,060
+2,597
+75% +$12.1K ﹤0.01% 6892
2018
Q3 		$22K Sell
3,463
-13,405
-79% -$99.7K ﹤0.01% 7048
2018
Q2 		$129K Buy
16,868
+1,244
+8% +$17.9K ﹤0.01% 5482
2018
Q1 		$350K Sell
15,624
-51
-0.3% -$1.13K ﹤0.01% 4364
2017
Q4 		$200K Buy
15,675
+13,665
+680% +$201K ﹤0.01% 5042
2017
Q3 		$31K Sell
2,010
-72
-3% -$1.02K ﹤0.01% 6245
2017
Q2 		$29K Sell
2,082
-4,282
-67% -$91.7K ﹤0.01% 6108
2017
Q1 		$140K Buy
+6,364
New +$135K ﹤0.01% 4952

Other funds holding JNCE

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACM
Ardent Capital Management Cincinnati, Ohio $241M AUM 23.63% 1-Year Est. Return

Citigroup's JNCE Position: Q1 2023 in Review

Citigroup sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2023, closing a stake of 425 shares — an estimated $472 sold.

Citigroup first reported a position in JNCE in Q1 2017 and held it in 24 quarters. The position peaked at $350K in Q1 2018. 84 funds tracked by Wall St. Rank hold JNCE as of Q1 2023.

  • Citigroup reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Citigroup sold 425 Jounce Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $472.
  • Citigroup first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 24 quarters.
  • Citigroup's Jounce Therapeutics, Inc. Common Stock position peaked at $350K in Q1 2018.
  • 84 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.